Does Stargardt Disease Cause Total Blindness? What to Know
At a Glance
Stargardt disease usually damages central vision and may meet legal-blindness criteria, but it generally does not cause total blindness. Many people retain light perception and useful side vision, although the amount of remaining vision varies.
Receiving a diagnosis of Stargardt disease often brings an immediate, terrifying question: Will I end up living in total darkness?
While it is impossible to guarantee any individual’s exact future, the typical disease course provides significant reassurance. Stargardt disease generally does not cause total blindness [1]. While the condition causes significant, progressive damage to your central vision, it most commonly leaves a functional degree of peripheral (side) vision intact. You will likely continue to see light, shapes, and movement.
Understanding Legal Blindness vs. Total Blindness
When eye care professionals discuss blindness in the context of Stargardt disease, they are almost always referring to legal blindness, which is very different from total blindness [2].
- Total blindness (medically termed “no light perception”) means a person sees absolutely nothing—complete darkness [2]. In natural history studies tracking cohorts of Stargardt patients over time, researchers observed individuals with severe visual decline, but none of them progressed to a complete loss of light perception [1].
- Legal blindness is an administrative, government-defined category used to determine eligibility for disability benefits, tax relief, and driving restrictions. In the United States, for example, you are considered legally blind if the visual acuity (sharpness of vision) in your better eye cannot be corrected with standard glasses to better than 20/200, or if your visual field (the total area you can see) is severely restricted to 20 degrees or less [3].
Because Stargardt disease progressively damages central vision, many patients do eventually reach the threshold for legal blindness [4]. The time it takes to reach this point varies immensely from person to person. For example, depending on your specific ABCA4 gene variants (the genetic mutations that cause the disease), the median time from symptom onset to legal blindness can be decades, while for others with different mutations, progression may happen earlier [4] [5].
The Macula and Peripheral Sparing
Stargardt disease primarily affects the macula, which is the small central area of the retina at the back of the eye. Your macula is responsible for your sharp, detailed, central vision—the vision you use to read, drive, thread a needle, and recognize faces. As the disease damages the macula, these central tasks become difficult.
However, the macula makes up only a tiny percentage of the retina. The rest of the retina provides your peripheral vision. For most patients, this outer vision is spared enough to remain highly useful for detecting motion and navigating physical spaces.
It is important to know, however, that peripheral vision is not always perfectly preserved. Some patients do develop peripheral retinal abnormalities, and advanced cases can occasionally develop widespread retinal changes that mimic other diseases [6] [7]. Your doctor can measure this using perimetry (a test that maps your entire visual field) [8] [4].
What This Means for Your Independence
While it is comforting to know that total darkness is highly unlikely [1], losing central vision still profoundly changes how you interact with the world. Even with preserved peripheral vision, you may experience challenges like central blind spots (scotomas), difficulty adapting to dark environments, and sensitivity to glare [9] [7].
Many people continue to navigate familiar places independently, but maximizing your safety and independence requires the right support:
- Low-Vision Specialists: Can prescribe specialized magnification tools, high-contrast displays, and screen-reading software tailored to your specific remaining vision.
- Occupational Therapy: Can teach you practical, safer ways to perform daily household and work tasks.
- Orientation and Mobility (O&M) Training: Can teach you how to travel safely, cross streets, and navigate unfamiliar environments using your remaining vision and mobility tools.
Grieving the loss of your central vision is entirely normal. By understanding the typical progression of the disease and connecting with rehabilitation professionals early, you can learn how to live confidently and actively with the vision you keep.
Common questions in this guide
Is complete blindness common with Stargardt disease?
How is legal blindness different from total blindness in Stargardt disease?
Will I keep my side vision if I have Stargardt disease?
Can ABCA4 variants predict how quickly Stargardt disease will progress?
What support can help me stay independent with Stargardt disease?
Questions to Ask Your Doctor
Curated prompts to bring to your next appointment.
- 1.Based on my current visual acuity and visual field map, how close am I to meeting the administrative criteria for legal blindness in our area?
- 2.Do my genetic test results (ABCA4 variants) give us any clues about my specific disease progression, recognizing that individual outcomes vary widely?
- 3.Can we perform a visual field test (perimetry) to document exactly how much of my peripheral vision is currently preserved?
- 4.At what point should I be referred to a low-vision specialist and an Orientation and Mobility (O&M) specialist to help me maximize my independence?
Questions For You
Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.
Related questions
References
References (9)
- 1
VISUAL ACUITY IN PATIENTS WITH STARGARDT DISEASE AFTER AGE 40.
Collison FT, Fishman GA
Retina (Philadelphia, Pa.) 2018; (38(12)):2387-2394 doi:10.1097/IAE.0000000000001903.
PMID: 29068916 - 2
Evaluation of blood flow in arteritic anterior ischemic optic neuropathy using laser speckle flowgraphy: A case series.
Yamaguchi C, Kiyota N, Himori N, et al.
American journal of ophthalmology case reports 2025; (38()):102316 doi:10.1016/j.ajoc.2025.102316.
PMID: 40236507 - 3
Ophthalmological manifestations, visual outcomes, and treatment of electrical and lightning trauma: A Systematic Review.
Piedrahita MA, Pineda-Vanegas AF, Moreno-Mendoza F, et al.
Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie 2025; (263(10)):2955-2973 doi:10.1007/s00417-025-06844-3.
PMID: 40576658 - 4
CLINICAL CHARACTERIZATION OF STARGARDT DISEASE PATIENTS WITH THE p.N1868I ABCA4 MUTATION.
Collison FT, Lee W, Fishman GA, et al.
Retina (Philadelphia, Pa.) 2019; (39(12)):2311-2325 doi:10.1097/IAE.0000000000002316.
PMID: 30204727 - 5
Stem Cell Ophthalmology Treatment Study (SCOTS): Bone Marrow-Derived Stem Cells in the Treatment of Stargardt Disease.
Weiss JN, Levy S
Medicines (Basel, Switzerland) 2021; (8(2)) doi:10.3390/medicines8020010.
PMID: 33546345 - 6
Insights into autofluorescence patterns in Stargardt macular dystrophy using ultra-wide-field imaging.
Kumar V
Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie 2017; (255(10)):1917-1922 doi:10.1007/s00417-017-3736-4.
PMID: 28689222 - 7
Different Phenotypes Represent Advancing Stages of ABCA4-Associated Retinopathy: A Longitudinal Study of 212 Chinese Families From a Tertiary Center.
Wang Y, Sun W, Zhou J, et al.
Investigative ophthalmology & visual science 2022; (63(5)):28 doi:10.1167/iovs.63.5.28.
PMID: 35608843 - 8
Barriers to Low-Vision Rehabilitation Services for Visually Impaired Patients in a Multidisciplinary Ophthalmology Outpatient Practice.
Khimani KS, Battle CR, Malaya L, et al.
Journal of ophthalmology 2021; (2021()):6122246 doi:10.1155/2021/6122246.
PMID: 34881054 - 9
ULTRAWIDEFIELD AUTOFLUORESENCE IN ABCA4 STARGARDT DISEASE.
Klufas MA, Tsui I, Sadda SR, et al.
Retina (Philadelphia, Pa.) 2018; (38(2)):403-415 doi:10.1097/IAE.0000000000001567.
PMID: 28248825
This page is for informational purposes only and does not constitute medical advice or predict your individual course. Your eye-care team can interpret your visual field and recommend appropriate low-vision support.
Get notified when new evidence is published on Stargardt disease.
We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.